Effector TherapeuticsEFTR
13F holders, Q3 2024 (September 30)2holders −14
0new positions
15sold out
$0.04avg. 13F price*
At the end of Q3 2024, 2 institutions reported holding Effector Therapeutics Inc. (EFTR) in their 13F filings, down 14 from Q2 2024. 0 opened new positions and 15 sold out. The largest holders were Sabby Management, LLC ($2K) and Barclays PLC ($4).
- Company
- Effector Therapeutics Inc.
- CUSIP
- 28202V207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 15 | $114K |
All 13F filers, Q2 2024 → Q3 2024: 686,045 shares sold, net −686,045 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Sabby Management, LLC | 0.03% | Reduce -82.5% | 61,758 | $2K |
| Barclays PLC | 0.00% | No change | 100 | $4 |
"% of holder's portfolio" is EFTR's weight in each manager's 13F, not the share of Effector Therapeutics Inc. the manager owns.